Kyprolis(Carfilzomib), a proteasome inhibitor, is suitable for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B-cell line.
Kyprolis is characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure. It is the second most common blood system in the world Tumors cannot be cured by traditional chemotherapy.
Bortezomib (brotezomib) is the first proteasome inhibitor and is the first-line drug for multiple myeloma. It has made a breakthrough in the treatment of multiple myeloma. Due to its strong drug resistance and people’s resistance to it’s continuous research on drug mechanism, Kyprolis, after bortezomib, was approved by the FDA as the second proteasome inhibitor, before receiving at least 2 drugs (including bortezomib and immunomodulators) for treatment )
Kyprolis is a specific and irreversible targeted inhibitor. It was originally developed by Proteolix and produced by Onyx Pharmaceuticals. It was approved by the FDA on July 20, 2012.
The finished product is presented as a sterile lyophilized powder for solution for infusion containing 60 mg/vial of carfilzomib as active substance. Other ingredients are Betadex sulfobutyl ether sodium, anhydrous citric acid and sodium hydroxide.
Betadex sulfobutyl ether sodium has been used in the formulation of Kyprolis playing a role of solubilization agent .Kyprolis contains betadex sulfobutyl ether sodium as below:
Kyprolis contains 530 mg betadex sulfobutyl ether sodium per 10.6 mg vial.
Kyprolis contains 1,600 mg betadex sulfobutyl ether sodium per 32 mg vial.
Kyprolis contains 3,000 mg betadex sulfobutyl ether sodium per 61.8 m mg vial.